These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 1346095)
1. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides. Wun TC Blood; 1992 Jan; 79(2):430-8. PubMed ID: 1346095 [TBL] [Abstract][Full Text] [Related]
2. Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas. Welsch DJ; Novotny WF; Wun TC Thromb Res; 1991 Oct; 64(2):213-22. PubMed ID: 1811340 [TBL] [Abstract][Full Text] [Related]
3. Immunoaffinity purification and characterization of lipoprotein-associated coagulation inhibitors from Hep G2 hepatoma, Chang liver, and SK hepatoma cells. A comparative study. Wun TC; Huang MD; Kretzmer KK; Palmier MO; Day KC; Bulock JW; Fok KF; Broze GJ J Biol Chem; 1990 Sep; 265(27):16096-101. PubMed ID: 2168880 [TBL] [Abstract][Full Text] [Related]
4. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Broze GJ; Warren LA; Novotny WF; Higuchi DA; Girard JJ; Miletich JP Blood; 1988 Feb; 71(2):335-43. PubMed ID: 3422166 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides. Ofosu FA; Modi GJ; Hirsh J; Buchanan MR; Blajchman MA Ann N Y Acad Sci; 1986; 485():41-55. PubMed ID: 2436525 [TBL] [Abstract][Full Text] [Related]
6. Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI. Lindahl AK; Abildgaard U; Larsen ML; Staalesen R; Hammer AK; Sandset PM; Nordfang O; Beck TC Thromb Res; 1991 Jun; 62(6):607-14. PubMed ID: 1926055 [TBL] [Abstract][Full Text] [Related]
9. Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation. Lindahl AK; Abildgaard U; Larsen ML; Aamodt LM; Nordfang O; Beck TC Thromb Res Suppl; 1991; 14():39-48. PubMed ID: 1658969 [TBL] [Abstract][Full Text] [Related]
10. Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharides. Sie P; Ofosu F; Fernandez F; Buchanan MR; Petitou M; Boneu B Br J Haematol; 1986 Dec; 64(4):707-14. PubMed ID: 2432917 [TBL] [Abstract][Full Text] [Related]
11. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Lindahl AK; Abildgaard U; Staalesen R Thromb Res; 1991 Oct; 64(2):155-68. PubMed ID: 1811336 [TBL] [Abstract][Full Text] [Related]
12. Utilization of a continuous flow reactor to study the lipoprotein-associated coagulation inhibitor (LACI) that inhibits tissue factor. Gemmell CH; Broze GJ; Turitto VT; Nemerson Y Blood; 1990 Dec; 76(11):2266-71. PubMed ID: 2257300 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms for the anticoagulant effect of heparin and related polysaccharides. Ofosu FA Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155 [TBL] [Abstract][Full Text] [Related]
14. Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma. Gerotziafas GT; Bara L; Bloch MF; Makris PE; Samama MM Blood Coagul Fibrinolysis; 1998 Oct; 9(7):571-80. PubMed ID: 9863704 [TBL] [Abstract][Full Text] [Related]